PLCG2 and B-cell chronic lymphocytic leukemia: Deep sensitivity genetic analysis of sequential samples of progressive CLL patients on ibrutinib allowed the detection of BTK- and/or PLCG2-mutated clones at a median of eight and nine months before progression, respectively [105,106].